6-氯-5-氮杂吲哚 | 74976-31-1

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 6-氯-5-氮杂吲哚
• 英文名称: 6-chloro-1H-pyrrolo[3,2-c]pyridine
• 英文别名: 6-chloro-5-azaindole
• CAS: 74976-31-1
• 化学式: C₇H₅ClN₂
• mdl: MFCD08690133
• 分子量: 152.583
• InChiKey: CBHXTZKXDLDMJZ-UHFFFAOYSA-N

物化性质

• 熔点：
  193-194 °C(Solv: benzene (71-43-2))
• 沸点：
  335.8±22.0 °C(Predicted)
• 密度：
  1.425±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Chloro-5-azaindole
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H333: May be harmful if inhaled
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Chloro-5-azaindole
CAS number: 74976-31-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H5ClN2
Molecular weight: 152.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

6-氯-5-氮杂吲哚可用作有机中间体，用于制备肾素抑制剂的重要中间体1H-吡咯[3,2-c]吡啶-6-醇。

合成方法

将N-碘琥珀酰亚胺(15.75g，70mmol)加入到2-氯吡啶-4-胺(9.00g，70mmol)的N,N′-二甲基甲酰胺(140mL)溶液中，并将混合物在80℃下搅拌6小时。随后加入另外的N-碘琥珀酰亚胺(7.80g，35mmol)，并将混合物在60℃下搅拌过夜。冷却至室温后，将溶剂减压蒸发，并将残余物在水和乙酸乙酯之间分配。有机层用饱和硫代硫酸钠水溶液、水和盐水洗涤，干燥(MgSO4)并浓缩。最后，通过快速层析法(6∶1到2∶1的己烷/乙酸乙酯)纯化残余物，得到2-氯-5-碘吡啶-4-胺(6.80g，38%)。

在氩气气氛下，向2-氯-5-碘吡啶-4-胺(1.95g，7.66mmol)的四氢呋喃(23mL)溶液中加入粉末状氢氧化钠(0.92g，23mmol)、四(三苯基膦)合钯(0)(0.17g，0.15mmol)，以及0.15M的三[(E)-2-乙氧基乙烯基]硼烷(20mL，3.0mmol)的四氢呋喃溶液。将得到的混合物在搅拌下加热到70℃并放置过夜。将混合物倾倒在水中，并用乙酸乙酯萃取。有机层用盐水洗涤、干燥后减压蒸发溶剂。通过快速层析法(6∶1到3∶1的己烷/乙酸乙酯)纯化残余物，得到2-氯-5-[(E)-2-乙氧基乙烯基]吡啶-4-胺(1.00g，62%)，为米色固体。

反应信息

• 作为反应物：
  描述：

  6-氯-5-氮杂吲哚 在 pyridinium tribromide 、 叔丁醇 作用下， 以97.6%的产率得到3,3-dibromo-6-chloro-1H-pyrrolo[3,2-c]pyridin-2(3H)-one
  参考文献：
  名称：

  TYROSINE KINASE 2 INHIBITORS AND USES THEREOF

  摘要：

  所提供的是式 (I) 的化合物：或其药学上可接受的盐，可用于抑制 TYK2 和治疗各种 TYK2 介导的病症或疾病。

  公开号：

  WO2023250064A1
• 作为产物：
  描述：

  2-chloro-5-[(E)-2-ethoxyvinyl]pyridin-4-amine 在 盐酸 、 potassium carbonate 作用下， 以 甲醇 、 水 为溶剂， 反应 21.0h， 以99%的产率得到6-氯-5-氮杂吲哚
  参考文献：
  名称：

  New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors

  摘要：

  这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂；其制备方法；包含它们的药物组合物；以及它们在治疗中的应用。

  公开号：

  EP2108641A1

文献信息

• [EN] SPIROCYCLIC INDOLINES AS IL-17 MODULATORS<br/>[FR] INDOLINES SPIROCYCLIQUES UTILISÉES COMME MODULATEURS D'IL-17
  申请人：UCB BIOPHARMA SPRL

  公开号：WO2018229079A1

  公开（公告）日：2018-12-20

  A series of substituted spirocyclic 2-oxoindoline derivatives, and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

  一系列替代的螺环式2-氧吲哚衍生物及其类似物，作为强效的人IL-17活性调节剂，因此在治疗和/或预防各种人类疾病，包括炎症性和自身免疫性疾病方面具有益处。
• TYK2 INHIBITORS AND USES THEREOF
  申请人：Nimbus Lakshmi, Inc.

  公开号：US20160251376A1

  公开（公告）日：2016-09-01

  The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物来抑制TYK2并治疗TYK2介导的疾病的方法。
• [EN] ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS<br/>[FR] ARYLOXYACÉTYLINDOLES ET ANALOGUES EN TANT QU'INHIBITEURS DE TOLÉRANCE AUX ANTIBIOTIQUES
  申请人：SPERO THERAPEUTICS INC

  公开号：WO2016112088A1

  公开（公告）日：2016-07-14

  The disclosure provides compounds and pharmaceutical compositions of aryloxyacetylindoles compounds and analogs useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds of general Formula (I) (I) or a pharmaceutically acceptable salt or prodrug thereof. Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a subject, including Pseudomonas aeruginosa infections, are also provided by the disclosure.

  该披露提供了芳基氧乙酰基吲哚化合物及类似物的化合物和药物组合物，用于治疗慢性和急性细菌感染。其中某些化合物是一般式(I)（I）的化合物或其药用可接受的盐或前药。该披露的某些化合物是MvfR抑制剂。MvfR抑制剂减少抗生素耐药细菌菌株的形成，对治疗革兰氏阴性细菌感染和减少铜绿假单胞菌的毒力有用。该披露还提供了治疗受试者细菌感染的方法，包括铜绿假单胞菌感染。
• [EN] AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS<br/>[FR] COMPOSÉS AMINOPYRIMIDINES EN TANT QU'INHIBITEURS DE MUTANTS D'EGFR CONTENANT T790M
  申请人：GENENTECH INC

  公开号：WO2014081718A1

  公开（公告）日：2014-05-30

  This invention relates to novel compounds of formula (I) which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer. (Formula I)

  这项发明涉及公式（I）的新化合物，这些化合物是T790M含有EGFR突变体的抑制剂，涉及含有它们的药物组合物，它们的制备方法，以及它们在预防或治疗癌症中的应用。
• [EN] AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES SUBSTITUÉS PAR UNE AMINE UTILISÉS COMME INHIBITEURS DE L'EHMT2 ET LEURS MÉTHODES D'UTILISATION
  申请人：EPIZYME INC

  公开号：WO2018118842A1

  公开（公告）日：2018-06-28

  The present disclosure relates to amine-substituted heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., cancer) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted heterocyclic heterocyclic compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.

  本公开涉及胺基取代的杂环化合物。本公开还涉及含有这些化合物的药物组合物，以及通过向需要的受试者施用本公开披露的胺基取代的杂环化合物或其药物组合物来抑制从EHMT1和EHMT2中选择的甲基转移酶酶，从而治疗疾病（例如，癌症）的方法。本公开还涉及利用这些化合物进行研究或其他非治疗目的。